|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||2.0999 - 2.1000|
|52 Week Range||2.0900 - 3.0500|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||7.39|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.50|
WAYNE, Pa., June 19, 2019 /PRNewswire/ -- Zyla Life Sciences (ZCOR) ("Zyla"), a growing commercial-stage life sciences company, announced the appointment of Gary M. Phillips, M.D. to its board of directors. "Gary brings to Zyla a wealth of experience from working in the pharmaceutical industry in a range of commercial, business development, strategy and clinical development leadership positions," said Timothy P. Walbert, Zyla chairman of the board and chairman, president and chief executive officer (CEO) of Horizon Therapeutics.
WAYNE, Pa., June 12, 2019 /PRNewswire/ -- Zyla Life Sciences (ZCOR) ("Zyla"), a growing commercial-stage life sciences company, announced the appointment of H. Jeffrey Wilkins, M.D. as senior vice president and chief medical officer (CMO) effective immediately. "With extensive clinical development, medical affairs and product evaluation experience, Dr. Wilkins brings invaluable capabilities as we continue to grow Zyla Life Sciences," said Bob Radie, president and chief executive officer.
-- Acquisition of five new products completed increasing net product sales to $17.6 million - an increase of more than 100% from the fourth quarter 2018 and 180% from the first quarter 2018 -- -- SG&A ...
WAYNE, Penn., May 14, 2019 /PRNewswire/ -- Egalet Corporation (ZCOR) ("Egalet"), a commercial-stage life sciences company focused on marketing treatments for different types of pain and inflammation, today announced that its first quarter 2019 financial results will be released on Thursday, May 16, 2019. Interested parties may listen to the call via a live audio webcast which may be accessed by visiting Egalet's website. Egalet, a commercial-stage life sciences company, is focused on marketing treatments for different types of pain and inflammation.